A new study published today in the journal PNAS (Proceedings of the National Academy of Sciences), has found that time of day and sleep deprivation have a significant effect on our metabolism. The finding could be crucial when looking at the best time of day to test for diseases such as cancer and heart disease, and for administering medicines effectively.
Researchers from the University of Surrey and The Institute of Cancer Research, London, investigated the links between sleep deprivation, body clock disruption and metabolism, and discovered a clear variation in metabolism according to the time of day.
Healthy male volunteers were put in an environment where light, sleep, meals and posture were controlled. Researchers collected blood samples every two hours to show how metabolic biomarkers change during the day. For the first 24 hours, the participants experienced a normal wake/sleep cycle. This was followed by 24 hours of wakefulness, to investigate the effect of sleep deprivation on metabolic rhythms. The results showed that metabolic processes are significantly increased during sleep deprivation. 27 metabolites, including serotonin, were found at higher levels in periods of sleep deprivation compared to levels during sleep.
Lead author Professor Debra Skene from the University of Surrey, said: "Our results show that if we want to develop a diagnostic test for a disease, it is imperative to take the time of day when taking blood samples into account, since this has a significant effect on metabolism. This is also key for administering medicines and determining when they will be at their most effective. Of course, this will have to be considered on a case-by-case basis, since many people such as shift workers will have a different sleep/wake cycle and timings will need to be adapted to their body clocks."
Co-Senior author, Dr Florence Raynaud, a group leader at The Institute of Cancer Research, London, said: "The study made accurate measurements of a large number of metabolites as they varied by time of day and under different sleep patterns. Our findings are likely to be important in interpreting the results of blood tests, and in understanding why some individuals respond differently to medication. They also set reference points for future studies looking at the connection between metabolic processes and diseases such as cancer."
The research was funded by a grant from the BBSRC awarded to a large team of researchers, and was conducted at the University of Surrey's Faculty of Health and Medical Sciences and at The Institute of Cancer Research, London.
Media enquiries: Peter La, Media Relations Office at the University of Surrey, Tel: 01483 689191 or E-mail: firstname.lastname@example.org
Notes to Editors:
About the University of Surrey
The University of Surrey is one of the UK's leading professional, scientific and technological universities with a world class research profile and a reputation for excellence in teaching and research. Ground-breaking research at the University is bringing direct benefit to all spheres of life – helping industry to maintain its competitive edge and creating improvements in the areas of health, medicine, space science, the environment, communications, defence and social policy. Programmes in science and technology have gained widespread recognition and it also boasts flourishing programmes in dance and music, social sciences, management and languages and law. In addition to the campus on 150 hectares just outside Guildford, Surrey, the University also owns and runs the Surrey Research Park, which provides facilities for 110 companies employing 2,750 staff.
About The Institute of Cancer Research, London
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public. The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.